About Caribou Biosciences
Caribou Biosciences is a company based in Berkeley (United States) founded in 2011 by Jennifer Doudna, James Berger, and Martin Jinek. Caribou Biosciences has raised $156.55 million across 6 funding rounds from investors including AbbVie, Pfizer and Novartis. The company has 147 employees as of December 31, 2024. Caribou Biosciences offers products and services including chRDNA Technology and CAR-T Cell Therapies. Caribou Biosciences operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Berkeley, United States
- Employees 147 as on 31 Dec, 2024
- Founders Jennifer Doudna, James Berger, Martin Jinek
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Caribou Biosciences, Inc.
-
Annual Revenue
$9.99 M (USD)-71.01as on Dec 31, 2024
-
Net Profit
-$149.1 M (USD)-46.08as on Dec 31, 2024
-
EBITDA
-$162.69 M (USD)-44.57as on Dec 31, 2024
-
Total Equity Funding
$156.55 M (USD)
in 6 rounds
-
Latest Funding Round
$25 M (USD), Post-IPO
Jun 29, 2023
-
Investors
AbbVie
& 24 more
-
Employee Count
147
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Caribou Biosciences
Caribou Biosciences is a publicly listed company on the NASDAQ with ticker symbol CRBU in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Caribou Biosciences
Caribou Biosciences offers a comprehensive portfolio of products and services, including chRDNA Technology and CAR-T Cell Therapies.
Enables precise CRISPR-based editing for gene knockout and insertion.
Develops off-the-shelf treatments for hematologic malignancies and diseases.
People of Caribou Biosciences
Unlock access to complete
Unlock access to complete
Leadership Team
25 people
Scientific Team
10 people
Software Development Team
6 people
Finance and Accounting
5 people
Operations Team
4 people
Legal and Compliance
4 people
Human Resources and Administration
2 people
Senior Team
2 people
Unlock access to complete
Funding Insights of Caribou Biosciences
Caribou Biosciences has successfully raised a total of $156.55M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Caribou Biosciences
Caribou Biosciences has secured backing from 25 investors, including institutional and venture fund investors. Prominent investors backing the company include AbbVie, Pfizer and Novartis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple investment strategies are pursued by this hedge fund.
|
Locked | Locked | Locked | |
|
Ridgeback Capital is focused on healthcare and life science investments.
|
Locked | Locked | Locked | |
|
Early-stage tech and life-sciences firms are funded across the US.
|
Locked | Locked | Locked |
Investor details for Caribou Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Caribou Biosciences
Investment portfolio details for Caribou Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Caribou Biosciences
Detailed financials for Caribou Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Caribou Biosciences Comparisons
Peer comparison for Caribou Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Caribou Biosciences
Caribou Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Cell-based therapies for cancer treatment are developed.
|
Detailed competitors of Caribou Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Caribou Biosciences
Complete news archive for Caribou Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Caribou Biosciences
Caribou Biosciences was founded in 2011 and raised its 1st funding round 2 years after it was founded.
Caribou Biosciences is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Caribou Biosciences is a funded company, having raised a total of $156.55M across 6 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Caribou Biosciences is 147.
Annual revenue of Caribou Biosciences is $9.99M as on Dec 31, 2024.
Caribou Biosciences was founded in 2011 in Berkeley, United States, within the biotechnology sector. Cellular engineering and analysis solutions are developed based on CRISPR-Cas9 biology. These tools are applied across therapeutics, agricultural biotechnology, biological research, and industrial biotechnology. CAR-T cell therapies for non-Hodgkin lymphoma and myeloid leukemia have been created, as have iPSC-derived CAR-NK therapies targeting solid tumors. Operations focus on advancing treatments for hematologic and oncologic conditions.
Caribou Biosciences's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Caribou Biosciences offers chRDNA Technology and CAR-T Cell Therapies.
Yes, Caribou Biosciences is publicly traded on NASDAQ under the ticker symbol CRBU.
Caribou Biosciences has 25 investors. Key investors include AbbVie, Pfizer, Novartis, Janus Henderson Investors, and Farallon Capital Management.
The ticker symbol of Caribou Biosciences is CRBU on NASDAQ.